Erin Salo‐Mullen

3.9k total citations
44 papers, 1.3k citations indexed

About

Erin Salo‐Mullen is a scholar working on Pathology and Forensic Medicine, Genetics and Cancer Research. According to data from OpenAlex, Erin Salo‐Mullen has authored 44 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 19 papers in Genetics and 17 papers in Cancer Research. Recurrent topics in Erin Salo‐Mullen's work include Genetic factors in colorectal cancer (22 papers), Cancer Genomics and Diagnostics (17 papers) and BRCA gene mutations in cancer (16 papers). Erin Salo‐Mullen is often cited by papers focused on Genetic factors in colorectal cancer (22 papers), Cancer Genomics and Diagnostics (17 papers) and BRCA gene mutations in cancer (16 papers). Erin Salo‐Mullen collaborates with scholars based in United States, Canada and Israel. Erin Salo‐Mullen's co-authors include Zsofia K. Stadler, David P. Kelsen, Eileen M. O’Reilly, Maeve A. Lowery, Kenneth H. Yu, Mark E. Robson, Robert C. Kurtz, Jinru Shia, Leonard B. Saltz and Kenneth Offit and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Erin Salo‐Mullen

42 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erin Salo‐Mullen United States 15 886 588 355 331 265 44 1.3k
Marjo van Puijenbroek Netherlands 22 814 0.9× 479 0.8× 878 2.5× 359 1.1× 210 0.8× 33 1.4k
Nils Rahner Germany 17 445 0.5× 331 0.6× 658 1.9× 310 0.9× 230 0.9× 35 1.0k
Michelle Landon United States 4 840 0.9× 542 0.9× 1.1k 3.2× 239 0.7× 238 0.9× 4 1.4k
Constanze Pagenstecher Germany 22 908 1.0× 630 1.1× 1.4k 3.8× 469 1.4× 254 1.0× 27 1.7k
Daniëlle Bodmer Netherlands 14 437 0.5× 485 0.8× 599 1.7× 522 1.6× 201 0.8× 21 1.2k
H. T. Lynch United States 9 885 1.0× 572 1.0× 911 2.6× 281 0.8× 545 2.1× 11 1.5k
Barbro Werelius Sweden 15 519 0.6× 299 0.5× 514 1.4× 444 1.3× 257 1.0× 23 1.1k
Ilene Comeras United States 7 1.3k 1.5× 744 1.3× 1.6k 4.6× 325 1.0× 236 0.9× 8 1.9k
Dominika Wokołorczyk Poland 23 302 0.3× 368 0.6× 377 1.1× 514 1.6× 815 3.1× 41 1.2k
Ingrid Marino United States 3 588 0.7× 420 0.7× 794 2.2× 185 0.6× 239 0.9× 3 1.0k

Countries citing papers authored by Erin Salo‐Mullen

Since Specialization
Citations

This map shows the geographic impact of Erin Salo‐Mullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Salo‐Mullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Salo‐Mullen more than expected).

Fields of papers citing papers by Erin Salo‐Mullen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Salo‐Mullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Salo‐Mullen. The network helps show where Erin Salo‐Mullen may publish in the future.

Co-authorship network of co-authors of Erin Salo‐Mullen

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Salo‐Mullen. A scholar is included among the top collaborators of Erin Salo‐Mullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Salo‐Mullen. Erin Salo‐Mullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salo‐Mullen, Erin, Julie O. Culver, Pamela Brock, et al.. (2025). Call to action for genetic counseling research in hereditary cancer: Considerations from the evidence‐based guidelines development process. Journal of Genetic Counseling. 34(3). e70026–e70026.
2.
Liu, Ying L., Karen A. Cadoo, Anna Maio, et al.. (2022). Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine. 24(6). 1187–1195. 10 indexed citations
3.
Salo‐Mullen, Erin, et al.. (2022). Attitudes toward preimplantation genetic testing and quality of life among individuals with hereditary diffuse gastric cancer syndrome. Hereditary Cancer in Clinical Practice. 20(1). 31–31. 3 indexed citations
4.
Yelskaya, Zarina, Angela G. Arnold, Laura H. Tang, et al.. (2021). Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. European Journal of Human Genetics. 29(7). 1103–1109. 1 indexed citations
5.
Quezada-Díaz, Felipe, Irbaz Hameed, Erin Salo‐Mullen, et al.. (2020). Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. Journal of the American College of Surgeons. 230(4). 669–675. 15 indexed citations
6.
Cadoo, Karen A., Semanti Mukherjee, Yelena Kemel, et al.. (2020). Characterization of patients with multiple primary tumors.. Journal of Clinical Oncology. 38(15_suppl). 1502–1502. 2 indexed citations
7.
Saldia, Amethyst, Sara H. Olson, Xiaolin Liang, et al.. (2019). Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prevention Research. 12(9). 599–608. 5 indexed citations
8.
Hu, Zishuo I., Jinru Shia, Zsofia K. Stadler, et al.. (2018). Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research. 24(6). 1326–1336. 266 indexed citations
9.
Salo‐Mullen, Erin, Patricio B. Lynn, Lu Wang, et al.. (2017). Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer. 17(1). 71–77. 9 indexed citations
10.
Lowery, Maeve A., David P. Kelsen, Marinela Capanu, et al.. (2017). Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer. 89. 19–26. 123 indexed citations
11.
Hamilton, Jada G., Margaux Genoff, Margaret Sheehan, et al.. (2017). Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment. 162(2). 297–306. 13 indexed citations
12.
Yelskaya, Zarina, Ruben Bacares, Erin Salo‐Mullen, et al.. (2016). CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5’ Splice Site. PLoS ONE. 11(11). e0165654–e0165654. 11 indexed citations
13.
O’Reilly, Eileen M., Maeve A. Lowery, Michal Segal, et al.. (2014). Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. Journal of Clinical Oncology. 32(15_suppl). 4023–4023. 30 indexed citations
14.
Salo‐Mullen, Erin, Jinru Shia, Isaac Brownell, et al.. (2014). Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. Familial Cancer. 13(3). 459–467. 13 indexed citations
15.
Arnold, Angela G., Ebunoluwa Otegbeye, Megan Harlan Fleischut, et al.. (2014). Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment. 145(3). 625–634. 9 indexed citations
16.
17.
Steinhagen, Emily, José G. Guillem, Erin Salo‐Mullen, et al.. (2012). The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. Clinical Colorectal Cancer. 11(4). 304–308. 39 indexed citations
18.
Salo‐Mullen, Erin, et al.. (2011). De novo CDH1 mutation in a family presenting with early‐onset diffuse gastric cancer. Clinical Genetics. 82(3). 283–287. 19 indexed citations
19.
Markowitz, Arnold J., et al.. (2011). Thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis (FAP): Memorial Sloan-Kettering Cancer Center (MSKCC) registry experience. Hereditary Cancer in Clinical Practice. 9(Suppl 1). P24–P24. 1 indexed citations
20.
Stadler, Zsofia K., Erin Salo‐Mullen, Nelly Sabbaghian, et al.. (2011). Germline PALB2 mutation analysis in breast–pancreas cancer families: Table 1. Journal of Medical Genetics. 48(8). 523–525. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marjo van Puijenbroek Breakdown of academic impact, for papers by Nils Rahner Breakdown of academic impact, for papers by Michelle Landon Breakdown of academic impact, for papers by Constanze Pagenstecher Breakdown of academic impact, for papers by Daniëlle Bodmer Breakdown of academic impact, for papers by H. T. Lynch Breakdown of academic impact, for papers by Barbro Werelius Breakdown of academic impact, for papers by Ilene Comeras Breakdown of academic impact, for papers by Dominika Wokołorczyk Breakdown of academic impact, for papers by Ingrid Marino
Rankless by CCL
2026